Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain

Clinical Drug Investigation

Volumn 30, Issue SUPPL. 2, 2010, Pages 31-38

  Gatti, Antonio ^a   Dauri, Mario ^a   Leonardis, Francesca ^a   Longo, Giuseppe ^a   Marinangeli, Franco ^a,b   Mammucari, Massimo ^a   Sabato, Alessandro Fabrizio ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; BUPRENORPHINE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HEADACHE; HEALTH; HUMAN; KARNOFSKY PERFORMANCE STATUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH; MUSCULOSKELETAL PAIN; NAUSEA; OUTPATIENT DEPARTMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; SHORT FORM 36; SKIN MANIFESTATION; SOCIAL BEHAVIOR; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VOMITING; CHRONIC DISEASE; INTRADERMAL DRUG ADMINISTRATION; ITALY; MIDDLE AGED; MUSCULOSKELETAL DISEASES; PAIN; SEVERITY OF ILLNESS INDEX; TIME; VERY ELDERLY;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC DISEASE; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; PAIN; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955121352     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/1158409-S0-000000000-00000     Document Type: Article

References (29)

1. Woolf AD, Zeidler H, Haglund U, et al. Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries. Ann Rheum Dis 2004 Apr; 63 (4): 342-347
2. National Institute for Clinical Excellence. Osteoarthritis: National clinical guideline for care and management in adults. 2008 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG059FullGuideline.pdf [Accessed 2010 May]
3. Punzi L, Doherty M, Zhang W, et al. Italian consensus on EULAR recommendations 2005 for the management of hip osteoarthritis. Reumatismo 2006 Oct-Dec; 58 (4): 301-309
4. Zhang W, Doherty M, Peat G, et al. EULAR evidencebased recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis 2010 Mar; 69 (3): 483-489
5. Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol 2006; 25 Suppl. 1: S22-9
6. Amato F, Bellinghieri F, Caruso G, et al. Dolore cronico non da cancro. Registro italiano buon uso degli oppiodi. Dati preliminari inerenti Buprenorphine TDS. It J Pain Manag Palliat Care 2005; (Suppl.): 1-15
7. Ambrosio F, Finco G, Mattia C, et al. SIAARTI recommendations for chronic non cancer pain. Minerva Anestesiol 2006; 72: 859-880
8. British Pain Society. Recommendations for the appropriate use of opioids for persistent non cancer pain - a consensus statement prepared on behalf of the Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Royal College of Psychiatrists. London: British Pain Society, 2005
9. Coluzzi F, Pappagallo M, National Initiative on Pain Control. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol 2005 Jul-Aug; 71 (7-8): 425-433
10. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003; 63 (19): 1999-2010; discussion 1-2
11. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006 May 23; 174 (11): 1589-1594
12. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice - a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 2005 Aug; 21 (8): 1147-1156
13. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004 Dec; 112 (3): 372-380
14. Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three shortterm clinical trials. Clin Ther 2006 Jun; 28 (6): 943-952
15. Muriel C, Failde I, Mico JA, et al. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, openlabel, uncontrolled, prospective, observational clinical study. Clin Ther 2005 Apr; 27 (4): 451-462
16. Sittl R. Nuijten M. Nautrup B.P. Changes in the prescribed daily doses of transdermal fentanyl and buprenorphine during treatment of patients with cancer and noncancer pain in Germany: Results of a retrospe
17. Sittl R, Nuijten M, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin Ther 2005 Jul; 27 (7): 1022-1031 (Pubitemid 41262460) 11): 1025-1036
18. Mor V, Laliberte L, Morris JN, et al. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984 May 1; 53 (9): 2002-2007
19. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984 Mar; 2 (3): 187-193
20. Fine PG, Mahajan G, McPherson ML. Long-acting opioids and short-acting opioids: appropriate use in chronic pain management. Pain Med 2009 Jul; 10 Suppl 2: S79-88
21. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am JMed 2009 Oct; 122 (10 Suppl.): S22-32
22. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009 Mar; 13 (3): 219-230
23. Vadivelu N, Hines RL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging 2008; 3 (3): 421-430
24. Karlsson M, Berggren AC. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150,and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther 2009 Mar; 31 (3): 503-513
25. Likar R, Lorenz V, Korak-Leiter M, et al. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Clin Ther 2007 Aug; 29 (8): 1591-1606
26. Gureje O, Von Korff M, Simon GE, et al. Persistent pain and well-being: a World Health Organization Study in Primary Care. [Erratum appears in JAMA 1998 Oct 7; 280(13): 1142]. JAMA 1998 Jul 8; 280 (2): 147-51
27. JAMA 1998 Jul 8; 280 (2): 147-151
28. Latham J, Davis BD. The socioeconomic impact of chronic pain. Disabil Rehabil 1994 Jan-Mar; 16 (1): 39-44
29. Sabato AF,Marineo G,Gatti A. Scrambler therapy. Minerva Anestesiol 2005 Jul-Aug; 71 (7-8): 479-482